JP2008508340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508340A5 JP2008508340A5 JP2007524264A JP2007524264A JP2008508340A5 JP 2008508340 A5 JP2008508340 A5 JP 2008508340A5 JP 2007524264 A JP2007524264 A JP 2007524264A JP 2007524264 A JP2007524264 A JP 2007524264A JP 2008508340 A5 JP2008508340 A5 JP 2008508340A5
- Authority
- JP
- Japan
- Prior art keywords
- low
- drug
- bioavailability
- specificity
- efflux
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000029142 excretion Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59870004P | 2004-08-03 | 2004-08-03 | |
| US60/598,700 | 2004-08-03 | ||
| PCT/EP2005/008369 WO2006013094A1 (en) | 2004-08-03 | 2005-08-02 | Methods for improving bioavailability of a renin inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008508340A JP2008508340A (ja) | 2008-03-21 |
| JP2008508340A5 true JP2008508340A5 (https=) | 2008-09-11 |
| JP5134366B2 JP5134366B2 (ja) | 2013-01-30 |
Family
ID=35056890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524264A Expired - Fee Related JP5134366B2 (ja) | 2004-08-03 | 2005-08-02 | レニン阻害剤のバイオアベイラビリティーの改善法 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7709532B2 (https=) |
| EP (2) | EP1776099B1 (https=) |
| JP (1) | JP5134366B2 (https=) |
| KR (1) | KR20070040384A (https=) |
| CN (1) | CN1993116B (https=) |
| AR (1) | AR050043A1 (https=) |
| AT (1) | ATE449601T1 (https=) |
| AU (1) | AU2005268844B2 (https=) |
| BR (1) | BRPI0514021A (https=) |
| CA (1) | CA2572743C (https=) |
| CY (1) | CY1109826T1 (https=) |
| DE (1) | DE602005017905D1 (https=) |
| DK (1) | DK1776099T3 (https=) |
| EC (1) | ECSP077169A (https=) |
| ES (1) | ES2335597T3 (https=) |
| HR (1) | HRP20100064T1 (https=) |
| IL (1) | IL180678A (https=) |
| MA (1) | MA28821B1 (https=) |
| MX (1) | MX2007001339A (https=) |
| MY (1) | MY142180A (https=) |
| NO (1) | NO20071142L (https=) |
| NZ (1) | NZ552903A (https=) |
| PE (1) | PE20060416A1 (https=) |
| PL (1) | PL1776099T3 (https=) |
| PT (1) | PT1776099E (https=) |
| RU (1) | RU2404758C2 (https=) |
| SI (1) | SI1776099T1 (https=) |
| TN (1) | TNSN07038A1 (https=) |
| TW (1) | TW200616610A (https=) |
| WO (1) | WO2006013094A1 (https=) |
| ZA (1) | ZA200610639B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| EP1927350A1 (en) * | 2006-11-24 | 2008-06-04 | Novartis AG | Methods for improving bioavailability of a renin inhibitor |
| CA2769392A1 (en) | 2009-07-31 | 2011-02-03 | Sandoz Ag | Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method |
| WO2012010651A2 (en) | 2010-07-23 | 2012-01-26 | Sandoz Ag | Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method |
| WO2014168255A1 (ja) * | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 巨核球の成熟化促進物質 |
| WO2015035218A1 (en) * | 2013-09-05 | 2015-03-12 | Howard University | Method of increasing the bioavailability of an hiv drug |
| JP6029621B2 (ja) * | 2014-07-14 | 2016-11-24 | ヤマサ醤油株式会社 | 血漿レニン活性の測定法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108499A (en) | 1993-02-04 | 2000-02-29 | Lilly Co Eli | Mammalian influx peptide transporter |
| US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| CA2224227A1 (en) | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| CN1143680C (zh) * | 1997-08-14 | 2004-03-31 | 阿旺蒂斯制药公司 | 增强非索非那定及其衍生物之生物利用度的方法 |
| JP2003512443A (ja) * | 1999-10-27 | 2003-04-02 | ベーカー ノートン ファーマシューティカルズ インコーポレイテッド | タキサンをヒト患者に経口投与するための方法及び組成物 |
| AU3808801A (en) * | 2000-02-11 | 2001-08-20 | Praecis Pharmaceuticals Incorporated | Methods for enhancing the bioavailability of a drug |
| WO2001092468A2 (en) * | 2000-05-31 | 2001-12-06 | Rutgers, The State University Of New Jersey | Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| GB0113663D0 (en) * | 2001-06-05 | 2001-07-25 | Novartis Ag | Use of organic compounds |
| KR20040066177A (ko) | 2001-12-19 | 2004-07-23 | 알자 코포레이션 | 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태 |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| EP1501546B1 (de) * | 2002-05-03 | 2012-10-10 | Hexal AG | Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer |
| PT1517682E (pt) * | 2002-06-28 | 2007-02-28 | Speedel Pharma Ag | Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo |
| NZ549535A (en) * | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
-
2005
- 2005-08-01 AR ARP050103198A patent/AR050043A1/es not_active Application Discontinuation
- 2005-08-01 PE PE2005000883A patent/PE20060416A1/es not_active Application Discontinuation
- 2005-08-02 BR BRPI0514021-8A patent/BRPI0514021A/pt not_active IP Right Cessation
- 2005-08-02 SI SI200530915T patent/SI1776099T1/sl unknown
- 2005-08-02 US US11/572,471 patent/US7709532B2/en not_active Expired - Fee Related
- 2005-08-02 MX MX2007001339A patent/MX2007001339A/es active IP Right Grant
- 2005-08-02 DE DE602005017905T patent/DE602005017905D1/de not_active Expired - Lifetime
- 2005-08-02 DK DK05769973.8T patent/DK1776099T3/da active
- 2005-08-02 AT AT05769973T patent/ATE449601T1/de active
- 2005-08-02 EP EP05769973A patent/EP1776099B1/en not_active Expired - Lifetime
- 2005-08-02 AU AU2005268844A patent/AU2005268844B2/en not_active Ceased
- 2005-08-02 WO PCT/EP2005/008369 patent/WO2006013094A1/en not_active Ceased
- 2005-08-02 JP JP2007524264A patent/JP5134366B2/ja not_active Expired - Fee Related
- 2005-08-02 CN CN2005800261744A patent/CN1993116B/zh not_active Expired - Fee Related
- 2005-08-02 TW TW094126194A patent/TW200616610A/zh unknown
- 2005-08-02 RU RU2007107850/15A patent/RU2404758C2/ru not_active IP Right Cessation
- 2005-08-02 PT PT05769973T patent/PT1776099E/pt unknown
- 2005-08-02 CA CA2572743A patent/CA2572743C/en not_active Expired - Fee Related
- 2005-08-02 HR HR20100064T patent/HRP20100064T1/hr unknown
- 2005-08-02 NZ NZ552903A patent/NZ552903A/en not_active IP Right Cessation
- 2005-08-02 PL PL05769973T patent/PL1776099T3/pl unknown
- 2005-08-02 MY MYPI20053584A patent/MY142180A/en unknown
- 2005-08-02 ES ES05769973T patent/ES2335597T3/es not_active Expired - Lifetime
- 2005-08-02 KR KR1020077002718A patent/KR20070040384A/ko not_active Abandoned
- 2005-08-02 EP EP09014648A patent/EP2191823A1/en not_active Withdrawn
-
2006
- 2006-12-18 ZA ZA200610639A patent/ZA200610639B/en unknown
-
2007
- 2007-01-11 IL IL180678A patent/IL180678A/en not_active IP Right Cessation
- 2007-01-15 EC EC2007007169A patent/ECSP077169A/es unknown
- 2007-02-02 TN TNP2007000038A patent/TNSN07038A1/en unknown
- 2007-02-22 MA MA29709A patent/MA28821B1/fr unknown
- 2007-02-28 NO NO20071142A patent/NO20071142L/no not_active Application Discontinuation
-
2010
- 2010-01-05 CY CY20101100019T patent/CY1109826T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2004000416A1 (es) | Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa. | |
| JP2009511595A5 (https=) | ||
| CY1118980T1 (el) | Στερεες μορφες ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου | |
| ATE474827T1 (de) | Hcv-replikationshemmer | |
| CL2009000305A1 (es) | Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv). | |
| CL2008001005A1 (es) | Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv. | |
| CL2007003250A1 (es) | Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc. | |
| EA200600498A1 (ru) | Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| ATE344056T1 (de) | Pharmazeutische zusammensetzungen für protease- hemmer für hepatitis-c-virus | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| NO2014009I2 (no) | Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser | |
| DE602004021120D1 (de) | Photopolymerisierbare zusammensetzung. | |
| FR14C0069I1 (fr) | Composition pharmaceutique comprenant le lurasidone | |
| CL2004001069A1 (es) | Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii. | |
| NO20080351L (no) | Anvendelse av sanglifehrin i HCV | |
| CL2007001004A1 (es) | Compuestos derivados peptidicos, inhibidores de proteasa, utiles para el tratamiento de una infeccion por el virus de la hepatitis c. | |
| CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| JP2008508340A5 (https=) | ||
| NL1028193A1 (nl) | Farmaceutisch werkzame verbindingen. | |
| EP1721335A4 (en) | CHIP HANDLING ON WAFER SCALE | |
| JP2009523456A5 (https=) | ||
| ATE409040T1 (de) | Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität | |
| DK1532279T3 (da) | Fremgangsmåde, sammensætning og kit til antigenbinding af Norwalk-lignende vira | |
| AR045724A1 (es) | Composicion farmaceutica orodispersable de un compuesto antitrombotico |